中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (3): 159-162.doi: 10.12144/zgmfskin202303159

• 论著 • 上一篇    下一篇

真实世界下奥马珠单抗治疗难治性正常补体性荨麻疹性血管炎疗效分析

陈晓萱1,2,赵晴2,张朝霞2,杨青2,陈声利2,刘红2,张福仁1,2   

  1. 1山东大学，山东济南，250012;
    2山东第一医科大学附属皮肤病医院（山东省皮肤病医院），山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2023-03-15 发布日期:2023-02-16

Efficacy of omalizumab in the treatment for refractory normocomplementemic vasculitis in real world

CHEN Xiaoxuan1,2, ZHAO Qing2, ZHANG Zhaoxia2, YANG Qing2, CHEN Shengli2, LIU Hong2, ZHANG Furen1,2   

  1. 1 Shandong University, Jinan 250012, China;
    2 Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2023-03-15 Published:2023-02-16

PDF (PC)

94

摘要： 目的：评估真实世界下奥马珠单抗对于治疗难治性正常补体性荨麻疹性血管炎（NUV）的有效性及安全性。方法：收集2016年1月至2022年3月就诊于山东省第一医科大学附属皮肤病医院的6例使用奥马珠单抗治疗难治性NUV患者的数据，通过荨麻疹性血管炎活动度评分（UVAS）和皮肤科生活质量指数（DLQI）评价治疗情况，每4周记录相应评分。并回顾文献，进行临床总结。结果：我院共治疗6例NUV患者，治疗时间12~32周。2例基线IgE高的患者，在第8周达到完全缓解；4例IgE正常的患者，均在第8周达到了部分缓解：缓解率100%。回顾既往报道的14例患者，发现300 mg/4周的剂量治疗NUV更普遍且有效。尚未发现患者发生不良反应。结论：奥马珠单抗治疗难治性正常荨麻疹性血管炎安全有效。

关键词: 奥马珠单抗, 荨麻疹性血管炎, 难治性

Abstract: Objective: To evaluate the efficacy and safety of omalizumab in the treatment of normocomplementemic vasculitis (NUV). Methods: The data of 6 patients with NUV treated with omalizumab in our hospital from January 2016 to March 2022 were collected. The efficiency was assessed through Urticarial vasculitis activity score (UVAS) and Dermatology Life Quality Index (DLQI) every 4 weeks. And the related literature were researched and analyzed. Results: A total of 6 patients were enrolled, with treatment duration ranging from 12 weeks to 32 weeks. Two patients with high IgE achieved partial remission at week 4 and complete remission at week 8, while the patients with normal IgE achieved partial remission at week 8 with remission rate of 100%. A dose of 300 mg/4 weeks was found to be more common and effective for the treatment of NUV based on the cases reported previously. There was no adverse reactions was found. Conclusion: Omalizumab is an effective and safe treatment for refractory normocomplementemic vasculitis.

Key words: omalizumab, urticarial vasculitis, refractory